Table 2.
Serum Levels of MMP-9 and MMP-2 of Relapsed and Nonrelapsed Depressed Patients after ECT
| Relapsed | Nonrelapsed | Control | ||
|---|---|---|---|---|
| n=18 | n=10 | n=40 | P | |
| MMP-9 (ng/mlL) | ||||
| At Pre-ECT or baseline | 513.5 ± 241.5 ns | 579.5 ± 257.1 ** | 481.5 ± 216.9 | .424b |
| At Post-ECT | [452.8 ± 158.1] | [348.2 ± 156.3] | .093a | |
| Magnitude of change from Pre-ECT to Post-ECT | -60.7 ± 174.1 | -231.3 ± 215.1 | .021a* | |
| MMP-2 (ng/mL) | ||||
| At Pre-ECT or baseline | 185.4 ± 39.0 | 187.5 ± 32.1 | 235.5 ± 56.8 | .001b |
| At Post-ECT | 207.4 ± 62.5 | 204.5 ± 33.8 | .415a | |
| Magnitude of change from Pre-ECT to Post-ECT | 22.0 ± 52.9 | 17.0 ± 35.4 | .811a | |
Abbreviation: ECT, electroconvulsive therapy; ns, not significant.
Data show the mean ± SD.
a P values of the Mann-Whitney U test.
b P values of Kruskal-Wallis test and Wilcoxon signed-rank test are reported.
*P<0.05, **P<0.01.